


This article was downloaded by: [McGill University Library]

On: 02 November 2014, At: 07:14

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/ganp20>

Three new lignan glycosides from the fruits of *Forsythia suspense*

Xin-Jia Yan^{ab}, Ying Peng^c, Zhi-Xiang Liu^{ab}, Jing Wen^{ab}, Qing-Bo Liu^{ab}, Ling-Zhi Li^{ab} & Shao-Jiang Song^{ab}

^a School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China

^b Key Laboratory of Structure-Based Drug Design & Discovery (Ministry of Education), Shenyang Pharmaceutical University, Shenyang 110016, China

^c School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China

Published online: 19 May 2014.

To cite this article: Xin-Jia Yan, Ying Peng, Zhi-Xiang Liu, Jing Wen, Qing-Bo Liu, Ling-Zhi Li & Shao-Jiang Song (2014) Three new lignan glycosides from the fruits of *Forsythia suspense*, *Journal of Asian Natural Products Research*, 16:6, 602-610, DOI: [10.1080/10286020.2014.917631](https://doi.org/10.1080/10286020.2014.917631)

To link to this article: <http://dx.doi.org/10.1080/10286020.2014.917631>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

Three new lignan glycosides from the fruits of *Forsythia suspense*

Xin-Jia Yan^{ab}, Ying Peng^c, Zhi-Xiang Liu^{ab}, Jing Wen^{ab}, Qing-Bo Liu^{ab}, Ling-Zhi Li^{ab}
and Shao-Jiang Song^{ab*}

^aSchool of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China; ^bKey Laboratory of Structure-Based Drug Design & Discovery (Ministry of Education), Shenyang Pharmaceutical University, Shenyang 110016, China; ^cSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China

(Received 22 January 2014; final version received 21 April 2014)

Two new lignan glycosides forsythiyanoside A (**1**) and forsythiyanoside B (**2**), one new stereoisomer of lignan glycoside (+)-8-hydroxypipinoresinol-4-*O*- β -D-glucopyranoside (**3**), together with seven known compounds (**4**–**10**), were isolated from the fruits of *Forsythia suspense* (Thunb.) Vahl. Compounds **4** and **10** were isolated from this species for the first time. The structures of **1**–**3** were elucidated on the basis of chemical and spectral analyses, including 1D and 2D NMR data and HR-ESI-MS. The absolute configurations were determined by the circular dichroism method. All isolates were tested for their cytotoxicities against five human cancer cell lines (A549, Colo-205, Hep-3B, HL60, and KB). In particular, compound **3** showed significant cytotoxicity with IC₅₀ values of 9.48, 7.75, 0.59, 4.06, and 38.38 μ M, respectively.

Keywords: *Forsythia suspense*; lignan glycosides; NMR; CD; cytotoxic activity

1. Introduction

Forsythia suspense (Thunb.) Vahl, a member of the family Oleaceae, is widely distributed in China including Henan, Shanxi, and Shandong Provinces. Its fruits are one of the most important original plants of Traditional Chinese Medicine which have been used for antibacterial, antiviral, anti-inflammation, diuretic, and antidotal purposes in oriental medicine [1]. The literature survey revealed that many kinds of compounds had been isolated from this plant, such as caffeoyl glycosides, phenylethanoid glycosides, lignans, terpenoids, alkaloids, and cyclohexylethanes [2,3]. In this paper, we describe the isolation and the structural elucidation of those new lignan glycosides, along with seven known compounds obtained from the 50% EtOH extract of *F. suspense*. Their structures (Figure 1) were established by extensive spectroscopic data

analysis and comparison with those of literature values. Meanwhile, all compounds were evaluated for their cytotoxicities against A549, Colo-205, Hep-3B, HL60, and KB cancer cell lines. Compound **3** showed significant cytotoxicity with IC₅₀ values of 9.48, 7.75, 0.59, 4.06, and 38.38 μ M, respectively, as compared with positive controls (5-fluorouracil: 25.72, 39.30, 4.80, 11.52, and 44.35 μ M, respectively; paclitaxel: 0.43, 7.80, 2.09, 0.01, and 1.00 μ M, respectively).

2. Results and discussion

Compound **1** was obtained as a colorless solid (MeOH), with the molecular formula C₂₇H₃₄O₁₂ as determined by the HR-ESI-MS at *m/z* 573.1942 [M + Na]⁺, indicating 11 degrees of unsaturation. The ¹H NMR spectrum of compound **1** (Table 1) displayed six aromatic proton signals at δ_{H}

*Corresponding author. Email: songsj99@163.com




Figure 1. The structures of compounds **1**, **2**, and **3**.

7.47 (1H, d, $J = 1.7$ Hz, H-2), 7.04 (1H, d, $J = 8.6$ Hz, H-5), 7.64 (1H, dd, $J = 8.6$, 1.7 Hz, H-6), 6.94 (1H, d, $J = 1.5$ Hz, H-2'), 7.01 (1H, d, $J = 8.5$ Hz, H-5'), and 6.83 (1H, dd, $J = 8.5$, 1.5 Hz, H-6'), which were assigned to two 1,3,4-trisubstituted benzene rings. In addition, the ^1H NMR spectrum also revealed two oxymethylene protons at δ_{H} 3.97 (1H, dd, $J = 8.4$, 5.2 Hz, H-9 β), 4.09 (1H, t, $J = 8.4$ Hz, H-9 α), and 3.44–3.50 (2H, m, H-9'), three methine protons at δ_{H} 4.14–4.17 (1H, m,

H-8), 4.56 (1H, d, $J = 8.0$ Hz, H-7'), and 2.49–2.52 (1H, m, H-8'), three methoxy groups at δ_{H} 3.72 (3H, s), 3.78 (3H, s), and 3.80 (3H, s), and a glucopyranosyl anomeric proton at δ_{H} 4.85 (1H, d, $J = 7.2$ Hz, H-1''). The ^{13}C NMR spectrum of **1** (Table 1) showed 27 carbon signals, apart from a glucose unit (δ_{C} 100.5, 73.7, 77.4, 70.2, 77.3, and 61.1) and three methoxy carbons at δ_{C} 56.0, 56.1, and 56.2, the remaining 18 carbons could be assigned to a tetrahydrofuranoid lignan




Figure 2. Key HMBC (\rightarrow) correlations of **1**, **2**, and **3**.

Table 1. ^1H NMR (600 MHz) and ^{13}C NMR (150 MHz) spectral data of compounds **1** and **2** in DMSO- d_6 .

No.	1		2	
	δ_{H}	δ_{C}	δ_{H}	δ_{C}
1		129.7		136.5
2	7.47 (d, 1.7)	111.1	6.92 (d, 1.6)	111.1
3		149.1		149.25
4		153.7		146.19
5	7.04 (d, 8.6)	111.4	7.04 (d, 8.4)	115.6
6	7.64 (dd, 8.6, 1.7)	123.6	6.82 (dd, 8.4, 1.6)	118.7
7		198.3	4.56 (d, 7.1)	83.0
8	4.14–4.17 (m)	49.3	1.62–1.65 (m)	52.7
9 α	4.09 (t, 8.4)	70.5	2.93–2.95 (m)	60.9
9 β	3.97 (dd, 8.4, 5.2)		3.06–3.08 (m)	
1'		135.9		131.2
2'	6.94 (d, 1.5)	111.3	6.75 (d, 1.7)	111.5
3'		149.2		148.0
4'		146.4		146.6
5'	7.01 (d, 8.5)	115.5	6.72 (d, 8.0)	115.6
6'	6.83 (dd, 8.5, 1.5)	119.1	6.62 (dd, 8.0, 1.7)	120.8
7'	4.56 (d, 8.0)	83.2	3.91 (d, 9.2)	85.7
8'	2.49–2.52 (m)	53.6	2.39–2.43 (m)	48.5
9' α	3.46–3.48 (m)	60.3	3.82 (dd, 8.8, 7.3)	70.8
9' β			4.05 (dd, 8.8, 4.4)	
1''	4.85 (d, 7.2)	100.5	4.88 (d, 7.3)	100.6
2''	3.21 (m)	73.7	3.25 (m)	73.7
3''	3.25 (m)	77.4	3.26 (m)	77.4
4''	3.12 (m)	70.2	3.16 (m)	70.1
5''	3.22 (m)	77.3	3.29 (m)	77.5
6''	3.62 (m)	61.1	3.46 (m)	61.2
	3.41 (m)		3.67 (m)	
–OCH ₃	3.72	56.1	3.77	56.2
–OCH ₃	3.78	56.0	3.73	56.0
–OCH ₃	3.80	56.2	3.06	56.2

Note: Coupling constants (J) in Hz are given in parentheses; chemical shift values are expressed in ppm.

skeleton [4]. The fact that the carbonyl group is connected to a part of the phenyl group was indicated by a carbonyl carbon signal at δ_{C} 198.3 and the conjugated property absorption peak shown in the IR spectrum at 1665 cm^{-1} . All of the above spectroscopic data were similar to those of vladinol D [5] with the exception of a methoxy and a glucose unit. Careful analysis of the correlations in the HSQC and HMBC spectra led to the establishment of the planar structure of compound **1** (Figure 1). The hydroxymethyl was linked to C-8', which was deduced from the long-rang correlations in the HMBC spectrum (Figure 2) from the protons at δ_{H} 3.46–

3.48 (2H, m) to C-8 (δ_{C} 49.3), C-8' (δ_{C} 53.6), and C-7' (δ_{C} 83.2). The correlations from H-7' at δ_{H} 4.56 (1H, d, $J = 8.0$ Hz) to C-2' (δ_{C} 111.3), C-6' (δ_{C} 119.1), and C-1' (δ_{C} 135.9) suggested that C-7' of tetrahydrofuran was connected with C-1' of the benzene ring. The correlations from H-9 at δ_{H} 3.97 (1H, dd, $J = 8.4, 5.2$ Hz, H-9 β), 4.09 (1H, t, $J = 8.4$ Hz, H-9 α) to C-7 (δ_{C} 198.3) indicated that the carbonyl carbon linked to C-8 of the tetrahydrofuran ring.

The relative configuration of **1** was determined by the analysis of ^1H NMR data and ROSEY correlations (Figure 3). The chemical shift of H-7' at δ_{H} 4.56 (1H, d, $J = 8.0$ Hz) suggested that H-7' and




Figure 3. Key ROSEY correlations for **1**.

H-8' were *trans*-oriented (for a *cis*-orientation of substituents at C-7' and C-8', the signal of H-7' was at around 5.5 ppm) [6,7], and this was supported by a ROSEY correlation between H-2' and H-8'. Based on ROSEY correlations of H-8/H-7', H-8/H-9', and H-7'/H-9', H-8 and H-7' were placed on the same side of the tetrahydrofuran ring (*trans*-orientation of H-8 and H-8'). The absolute configuration of **1** was established by the analysis of its circular dichroism (CD) spectrum. A negative Cotton effect at 321 nm and a positive Cotton effect at 294 nm were shown in the CD spectrum of **1**, indicating the (8*S*,7'*S*,8'*R*)-configuration [4,8] in **1**. The anomeric proton at δ_{H} 4.85 (1H, d, $J = 7.2$ Hz, H-1'') indicated the β -configuration of glucose unit. The component sugar was determined to be D-glucopyranose based on comparison of the acid hydrolyzate of **1** with authentic D-glucopyranose by thin layer chromatography (TLC) and gas chromatography (GC) analyses [9]. In the HMBC spectrum (Figure 2), the anomeric proton at δ_{H} 4.85 showed a long-range correlation with the aromatic carbon signal at δ_{C} 146.4

which was assigned to C-4'. Thus, the structure of **1** was determined as (8*S*,7'*S*,8'*R*)-4',9'-dihydroxy-3,4,3'-trimethoxy-7',9-epoxy lignan-7-oxo-4'- β -D-glucopyranoside, named forsythiyanoside A.

Compound **2** was obtained as a sticky oil (MeOH) and possessed a molecular formula $\text{C}_{27}\text{H}_{36}\text{O}_{12}$, as revealed from its HR-ESI-MS analysis (m/z 575.2098 $[\text{M} + \text{Na}]^+$), indicating 10 degrees of unsaturation. The ^1H NMR spectrum (Table 1) showed proton signals of two ABX systems of aromatic protons [δ_{H} 6.92 (1H, d, $J = 1.6$ Hz, H-2), 7.04 (1H, d, $J = 8.4$ Hz, H-5), 6.82 (1H, dd, $J = 8.4, 1.6$ Hz, H-6), 6.75 (1H, d, $J = 1.7$ Hz, H-2'), 6.72 (1H, d, $J = 8.0$ Hz, H-5'), and 6.62 (1H, dd, $J = 8.0, 1.7$ Hz, H-6')], two aromatic CH_3O groups [δ_{H} 3.73 (3H, s) and 3.77 (3H, s)], indicating the presence of two trisubstituted benzene rings. Six oxygenated aliphatic protons [δ_{H} 4.56 (1H, d, $J = 7.1$ Hz, H-7), 2.93–2.95 (1H, m, H-9 α), 3.06–3.08 (1H, m, H-9 β), 3.91 (1H, d, $J = 9.2$ Hz, H-7'), 3.82 (1H, dd, $J = 8.8, 7.3$ Hz, H-9' α), and 4.05 (1H, dd, $J = 8.8, 4.4$ Hz, H-9' β)], together with two




Figure 4. Key NOESY correlations for **2**.

aliphatic protons [δ_{H} 1.62–1.65 (1H, m, H-8) and 2.39–2.43 (1H, m, H-8')] were evidences for the presence of a tetrahydrofuranoid lignan skeleton which were similar with compound **1**. In the ^{13}C NMR spectrum (Table 1), apart from the 12 aromatic, a glucose unit, and three methoxyl signals, there were six sp^3 C-atoms, including two oxymethines [δ_{C} 83.0 and 85.7] and two oxymethylenes [δ_{C} 60.9 and 70.8]. The remaining CH_3O group was located at C-7', based on the HMBC correlation (Figure 2) between CH_3O group protons at δ_{H} 3.06 (3H, s) and C-7' (δ_{C} 85.7). The correlations from H-7 at δ_{H} 4.56 (1H, d, $J = 7.1$ Hz) to C-2 (δ_{C} 111.1), C-6 (δ_{C} 118.7), and C-1 (δ_{C} 136.5) suggested that C-7 of tetrahydrofuran was connected with C-1 of the benzene ring. The correlations from H-9' at δ_{H} 3.82 (1H, dd, $J = 8.8, 7.3$ Hz, H-9' α), 4.05 (1H, dd, $J = 8.8, 4.4$ Hz, H-9' β) to C-7' (δ_{C} 85.7), from H-7' at δ_{H} 3.91 (1H, d, $J = 9.2$ Hz) to C-8' (δ_{C} 48.5), C-9' (δ_{C} 70.8), C-2' (δ_{C} 115.5), and C-6' (δ_{C} 120.8) indicated that C-7' linked to C-2' of the benzene and C-8' of the tetrahydrofuran ring.

The relative configuration in the tetrahydrofuran ring was determined by

the H-7 chemical shift and NOESY experiment. According to a signal of H-7 at δ_{H} 4.56, the orientation of H-7/H-8 of compound **2** was determined to be *trans* [10,11]. All *trans*-orientation of H-7/H-8/H-8' was determined by the cross-peak of H-7/H-9, H-7/H-8', and H-9/H-8' in the NOESY spectrum (Figure 4). The CD spectrum of **2** showed two positive peaks at 240 and 283 nm similar to those of analogous compound tinosposide B [12], indicating that C-7, C-8, and C-8' in **2** have *S*, *R*, and *S*-configurations, respectively. However, there were no definitive conclusions on the relationships between the absolute configuration of C-7' and CD in this series of tetrahydrofuranoid lignans [11,13]. Acid hydrolysis of **2** afforded D-glucose by TLC and GC analyses [9]. The β -configuration anomeric proton of glucose at δ_{H} 4.88 (1H, d, $J = 7.3$ Hz) showed HMBC correlations with the aromatic C-4 at δ_{C} 146.1. Accordingly, compound **2** was established as (7*S*,8*R*,8'*S*)-4,9,4'-trihydroxy-3,3',7'-trimethoxy-7,9'-epoxylignan-4-*O*- β -D-glucopyranoside, named forsythiyanoside B.

Compound **3** was obtained as a yellow amorphous powder. Its molecular formula

Table 2. ^1H NMR (400 MHz) and ^{13}C NMR (100 MHz) spectral data of compound **3** in $\text{DMSO-}d_6$.

No.	3	
	δ_{H}	δ_{C}
1		131.4
2	7.00 (d, 1.8)	112.9
3		147.8
4		146.4
5	6.75 (d, 8.2)	115.6
6	6.89 (dd, 8.2, 1.8)	120.3
7	4.29 (s)	88.8
8		90.6
9	3.50 (d, 9.0)	75.9
	4.16 (d, 9.0)	
1'		129.9
2'	6.86 (d, 1.0)	110.2
3'		148.7
4'		145.8
5'	7.03 (d, 8.6)	115.0
6'	6.73 (dd, 8.6, 1.0)	118.3
7'	5.08 (d, 5.2)	81.1
8'	2.01–3.04 (m)	57.6
9'	3.03–3.05 (m)	67.9
	3.82–3.85 (m)	
1''	4.87 (d, 7.3)	100.7
2''	3.17 (m)	77.4
3''	3.26 (m)	73.7
4''	3.17 (m)	70.2
5''	3.28 (m)	77.3
6''	3.47 (m)	61.1
	3.68 (m)	
–OCH ₃	3.75	56.0
–OCH ₃	3.76	56.0

Note: Coupling constants (J) in Hz are given in parentheses; chemical shift values are expressed in ppm.

was established as $\text{C}_{26}\text{H}_{32}\text{O}_{12}$ by HR-ESI-MS analysis (m/z 559.1791 $[\text{M} + \text{Na}]^+$). The ^1H and ^{13}C NMR signals (Table 2) were assigned by the DEPT, HSQC, and HMBC analyses, indicating the presence of one glucosyl and two guaiacyl groups. Two characteristic downfield CH signals at δ_{H} 5.08 (1H, d, $J = 5.2$ Hz) and 4.29 (1H, s) and six characteristic aliphatic carbon signals at δ_{C} 81.1 (CH), 57.6 (CH), 67.9 (CH_2), 88.8 (CH), 90.6 (CH), and 75.9 (CH_2) suggested that compound **3** was a 8-hydroxyfuranoid lignan. In the HMBC spectrum (Figure 2), the cross-

peaks of H-7 with C-9, C-8', C-9', and C-1 and H-7' with C-9', C-8, C-9, and C-1' supported 7.O.9' and 7'.O.9 oxygen bridges in the ditetrahydrofuran ring moiety. The relative and absolute configurations of the aglycone of compound **3** were determined by comparison of its NMR data and CD spectrum with those of known analogous compounds [14,15]. The ^{13}C NMR spectrum was important in establishing the orientation of the aryl groups. For an equatorial guaiacyl group, C-1' appeared in downfield at around δ_{C} 131.3 in $\text{DMSO-}d_6$, while for an axial guaiacyl group, C-1' appeared in upfield at around δ_{C} 129.6 [3,14]. Thus, considering the solvent effect on the aryl group, the value of C-1' at δ_{C} 129.9 in compound **3** accounted for the appearance of axial guaiacyl group. These spectroscopic data suggested that **3** and known compound (+)-1-hydroxypinoresinol-4'- O - β -D-glucopyranoside [14] are epimers at C-7'. Thus, the relative configuration could be proposed as 7,8-*cis*-8,8'-*cis*-7',8'-*trans*. The CD spectrum of compound **3** was identical with that of (+)-1-hydroxy-6-epipinoresinol which has the absolute configuration 7*R*, 8*S*, 7'*R*, and 8'*R* [14–16]. Therefore, the aglycon of compound **3** was (+)-1-hydroxy-6-epipinoresinol. Acid hydrolysis of **3** afforded D-glucose by TLC and GC analyses [9]. The β -configuration anomeric proton of glucose at δ_{H} 4.87 (1H, d, $J = 7.3$ Hz) showed HMBC correlation with the aromatic C-atom C-4 (δ_{C} 146.4). Accordingly, compound **3** was established as (+)-8-hydroxyepipinoresinol-4- O - β -D-glucopyranoside.

The known compounds were readily identified as glochidioboside (**4**) [17], (+)-pinoresinol-4- O - β -D-glucopyranoside (**5**) [18], (+)-epipinoresinol-4- O - β -D-glucopyranoside (**6**) [18], (+)-epipinoresinol-4'- O - β -D-glucopyranoside (**7**) [18], (+)-phyllirin (**8**) [18], (–)-matairesinoside (**9**) [18], and (+)-isolariciresino-9- O - β -D-glucopyranoside (**10**) [19] by comparing

NMR spectral data with those reported in the literature.

All isolated compounds were evaluated for their cytotoxic activities against lung cancer (A549), colon cancer (Colo-205), hepatoma (Hep-3B), leucocythemia (HL-60), and cervical cancer (KB) cell lines by the MTT method [20], using 5-fluorouracil and paclitaxel as positive controls. Compound **3** showed cytotoxicity against the five human cancer cell lines with IC_{50} values of 9.48, 7.75, 0.59, 4.06, and 38.38 μM , respectively, and was more cytotoxic than 5-fluorouracil (25.72, 39.30, 4.80, 11.52, and 44.35 μM , respectively). Meanwhile, compound **3** displayed similar cytotoxicity to paclitaxel ($IC_{50} = 7.80 \mu\text{M}$) against Colo-205 cells and more cytotoxic than paclitaxel ($IC_{50} = 2.09 \mu\text{M}$) against Hep-3B cells. Other isolates (**1**, **2**, **4–10**) are inactive.

3. Experimental

3.1 General experimental procedures

Optical rotations were measured on a JASCO-P-1020 Polarimeter (Jasco Co., Tokyo, Japan). UV spectra were carried out on a Shimadzu UV-1700 spectrophotometer (Shimadzu Corporation, Kyoto, Japan). IR spectra were obtained on a Shimadzu FTIR-8400S spectrophotometer (Shimadzu Corporation). NMR spectra were recorded on Bruker ARX-400 and ARX-600 instruments (Bruker Co., Billerica, MA, USA). HR-ESI-TOF-MS experiments were carried out on a Micro TOF spectrometer (Bruker Co., Karlsruhe, Germany). CD spectra were measured by Bio-Logic (MOS 450) spectrophotometer. High-performance liquid chromatography (HPLC) preparation was carried out on a Hitachi preparative HPLC system (Hitachi Ltd, Tokyo, Japan) equipped with Refractive Index Detector (L-2490) and prep-ODS (10 mm \times 250 mm). GC was done on an Agilent 7890A Gas Chromatograph (Agilent Technologies, Inc., Santa Clara, CA, USA) equipped with HP-5 capillary

column (30 m \times 320 mm \times 0.25 μm). Sephadex LH-20 (20–100 μm , Pharmacia Fine Chemical Co. Ltd, Piscataway, NJ, USA), silica gel (200–300 mesh, Qingdao Marine Chemistry Ltd, Qingdao, China), macroporous resin (D101, Cangzhou Bon Adsorber Technology Co., Ltd, Cangzhou, China), and Cosmosil octadecyl silane (ODS; 40–80 μm , Nacalai Tosoh, Inc., Uetikon, Switzerland) were used for column chromatography (CC). TLC was conducted on silica gel GF254 (Qingdao Marine Chemistry Ltd).

3.2 Plant material

The fruits (8.3 kg) of *F. suspense* were collected from Henan Province of China in June 2009, and authenticated by Prof. Jin-Cai Lu, Department of Pharmacognosy, Shenyang Pharmaceutical University. The voucher specimen (No. 20091011) is kept in the Nature Products Laboratory of Shenyang Pharmaceutical University, Shenyang, China.

3.3 Extraction and isolation

The fruits of *F. suspense* (8.3 kg) were crushed to pieces and refluxed with 50% EtOH for three times. The extract was evaporated under reduced pressure to afford a residue (350 g). The residue was suspended in H_2O and then successively extracted with CHCl_3 , EtOAc, and *n*-butanol. The *n*-butanol extract was evaporated *in vacuo* to give a residue (100 g), which was chromatographed over D101 macroporous resin and a gradient of aqueous EtOH (water, 30%, 60%, and 95%, v/v) to yield four major fractions (A–D). Fraction C (55.0 g) was subjected to silica gel CC (12 \times 60 cm) with a gradient mixture of CH_2Cl_2 –MeOH (100:0–50:50) to afford five fractions (1–5). Fraction 2 (22.4 g) was further purified over an ODS column chromatography (4 \times 45 cm) using MeOH and H_2O as the mobile phases with a gradient from

20% to 60% to afford fractions F₂₋₁–F₂₋₈ based on HPLC analysis. F₂₋₂ (6.1 g) was subjected to another silica gel CC (2 × 30 cm) and eluted with CH₂Cl₂:MeOH:water (8:2:0.25) to afford fractions F₂₋₂₋₁–F₂₋₂₋₅ based on TLC analysis. F₂₋₂₋₂ (500 mg) was subjected to preparative HPLC eluted with CH₃OH–H₂O (15:85) at 3 ml/min (*t*_R 15 and 17 min) to yield compounds **4** (15 mg) and **9** (36 mg). F₂₋₂₋₃ (200 mg) was subjected to semi-preparative HPLC eluted with CH₃CN–H₂O (10:90) at 3.5 ml/min (*t*_R 15 min) to yield **2** (10 mg), 3.5 ml/min (*t*_R 20 min) to yield **3** (9 mg), and 3.5 ml/min (*t*_R 23 min) to yield **7** (15 mg). F₂₋₃ (2.0 g) was subjected to semi-preparative HPLC eluted with CH₃CN–H₂O (20:80) at 3.5 ml/min (*t*_R 20 min) to yield **1** (20 mg). Fraction 3 (18.0 g) was further purified over an ODS column chromatography (4 × 45 cm) using MeOH and H₂O as the mobile phase with a gradient from 10% to 60% to afford fractions F₃₋₁–F₃₋₄ based on HPLC analysis. F₃₋₂ (10.0 g) was subjected to semi-preparative HPLC eluted with CH₃CN–H₂O (25:75) at 3.5 ml/min (*t*_R 16 min) to yield **5** (30 mg), 3.5 ml/min (*t*_R 23 min) to yield **6** (20 mg), and 3.5 ml/min (*t*_R 40 min) to yield **10** (10 mg). Fraction 4 (2.0 g) was subjected to semi-preparative HPLC eluted with CH₃CN–H₂O (25:75) at 3.5 ml/min (*t*_R 18 min) to yield **8** (100 mg).

3.3.1 Forsythiyanoside A (**1**)

Colorless solid (MeOH); $[\alpha]_D^{25} - 12.4$ (*c* = 0.10, MeOH). IR (KBr) ν_{\max} (cm⁻¹): 3405, 2919, 2850, 1665, 1594, 1514, 1384, 1263, and 1046; UV (MeOH) λ_{\max} : 206.6, 227.6, 275.6, and 302.2 nm; CD (MeOH): $\Delta\epsilon_{235.2\text{ nm}} - 10.17$, $\Delta\epsilon_{276.0\text{ nm}} - 5.83$, $\Delta\epsilon_{294.0\text{ nm}} + 3.48$, $\Delta\epsilon_{321.0\text{ nm}} - 1.25$; for ¹H and ¹³C NMR spectral data (DMSO-*d*₆), see Table 1; HR-ESI-MS: *m/z* 573.1942 [M + Na]⁺ (calcd for C₂₇H₃₄O₁₂Na, 573.1942).

3.3.2 Forsythiyanoside B (**2**)

Sticky oil (MeOH); $[\alpha]_D^{25} - 10.3$ (*c* = 0.05, MeOH). IR (KBr) ν_{\max} (cm⁻¹): 3440, 2918, 2850, 1631, 1466, 1384, 1128, and 1075; UV (MeOH) λ_{\max} : 207.0, 227.4, and 278.6 nm; CD (MeOH): $\Delta\epsilon_{205.1\text{ nm}} - 4.80$, $\Delta\epsilon_{240.0\text{ nm}} + 4.69$, $\Delta\epsilon_{283.4\text{ nm}} + 8.73$; for ¹H and ¹³C NMR spectral data (DMSO-*d*₆), see Table 1; HR-ESI-MS: *m/z* 575.2098 [M + Na]⁺ (calcd for C₂₇H₃₆O₁₂Na, 575.2099).

3.3.3 (+)-8-Hydroxyepipinoresinol-4-O-β-D-glucopyranoside (**3**)

Yellow amorphous powder (MeOH); $[\alpha]_D^{25} - 8.1$ (*c* = 0.05, MeOH). IR (KBr) ν_{\max} (cm⁻¹): 3441, 2919, 2850, 1632, 1384, and 1129; UV (MeOH) λ_{\max} : 207.2, 227.0, and 278.2 nm; CD (MeOH): $\Delta\epsilon_{218.4\text{ nm}} - 3.72$, $\Delta\epsilon_{236.0\text{ nm}} + 4.23$, $\Delta\epsilon_{278.2\text{ nm}} - 7.21$; for ¹H and ¹³C NMR spectral data (DMSO-*d*₆), see Table 2; HR-ESI-MS: *m/z* 559.1791 [M + Na]⁺ (calcd for C₂₆H₃₂O₁₂Na, 559.1786).

3.4 Acid hydrolysis of compounds 1–3

Each compound (3.0 mg) was hydrolyzed with 2 M HCl (5.0 ml), heated for 4 h at 95°C and extracted with CHCl₃ (3 × 5.0 ml). Then, the aqueous layer was concentrated *in vacuo* to appropriate volume, and the solution was examined by TLC (EtOAc–BuOH–H₂O–HOAc, 4:4:1:1), and compared with the authentic sample, glucose was detected. Each remaining aqueous layer was concentrated to dryness to give a residue, which was dissolved in pyridine (1.0 ml), and then L-cysteine methyl ester hydrochloride (2.0 mg) was added to the solution. The mixture was heated at 60°C for 2 h, and 0.5 ml of *N*-tremethylsilylimidazole was added, followed by heating at 60°C for 2 h. The reaction product was subjected to GC analysis on Agilent 7890A (HP-5, 30 m × 320 mm, 0.25 μm) with flame ionization detector detection. Column temperature:

120–280°C with the rate of 8°C/min, and the carrier gas was N₂ (1.4 ml/min); injection temperature: 250°C; injection volume: 1 µl. The absolute configuration of the monosaccharides was confirmed to be D-Glu by comparison of the retention time of its Me₃Si ethers with standard sample [*t*_R (D-glucose) = 25.873 min].

3.5 Cytotoxicity assay

Human malignant leucocythemia cell lines HL-60, hepatoma cell lines Hep-3B, colon cancer cell lines Colo-205, cervical cancer lines KB, and lung cancer cell lines A549 were obtained from the National Center for Medical Culture Collection (Shanghai, China). They were routinely cultured in Roswell Park Memorial Institute (RPMI) 1640 or Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum and maintained at 37°C in a humidified incubator with 5% CO₂. The *in vitro* cell viability effects of compounds were determined by MTT assay [20]. The cells (1 × 10⁵ cells/ml) were seeded into 96-well culture plates. After overnight incubation, the cells were treated with various concentrations of agents for 72 h. Then, 10 µl of MTT solution (2.5 mg/ml in phosphate-buffered saline) was added to each well, and the plates were incubated for an additional 4 h at 37°C. After centrifugation (200g, 10 min), the medium with MTT was aspirated, followed by the addition of 100 µl of DMSO. The optical density of each well was measured at 492 nm with a Biotek Synergy TM HT Reader.

Acknowledgment

Authors thank Mrs Wen Li and Mr Yi Sha of Shenyang Pharmaceutical University for the recording of NMR spectra.

References

- [1] X.T. Liang, *Common Traditional Chinese Medicine Foundation Research* (Science Press, Beijing, 2003), Vol. 1, p. 315.
- [2] D.S. Ming, D.Q. Yu, S.S. Yu, and J. Asian, *Nat. Prod. Res.* **1**, 327 (1999).
- [3] D.L. Liu, S.X. Xu, Y. Xu, and W.F. Wang, *J. Chin. Pharm. Sci.* **7**, 49 (1998).
- [4] Y.N. Yang, F. Zhang, Z.M. Feng, J.S. Jiang, P.C. Zhang, and J. Asian, *Nat. Prod. Res.* **14**, 981 (2012).
- [5] R.X. Tan, J. Jakupovic, and J. Jia, *Planta Med.* **56**, 475 (1990).
- [6] K.Y. Jung, D.S. Kim, S.R. Oh, S.H. Park, I.S. Lee, J.J. Lee, D.H. Shin, and H.K. Lee, *J. Nat. Prod.* **61**, 808 (1998).
- [7] S.G. Liao, Y. Wu, and J.M. Yue, *Helv. Chim. Acta* **89**, 73 (2006).
- [8] N. Harada and K. Nakanishi, *J. Am. Chem. Soc.* **91**, 3989 (1969).
- [9] E.L. Regalado, D. Tasdemir, M. Kaiser, N. Cachet, P. Amade, and O.P. Thomas, *J. Nat. Prod.* **73**, 1404 (2010).
- [10] Y.L. Huang, C.C. Chen, Y.P. Chen, H.Y. Hsu, and Y.H. Kuo, *Planta Med.* **56**, 237 (1990).
- [11] Y.L. Ma, Q.L. Huang, and G.Q. Han, *Phytochemistry* **41**, 287 (1996).
- [12] W. Li, K. Koike, L.J. Liu, L.B. Lin, X.W. Fu, Y.J. Chen, and T. Nikaido, *Chem. Pharm. Bull.* **52**, 638 (2004).
- [13] J. Lee, D. Lee, D.S. Jang, J.W. Nam, J.P. Kim, K.H. Park, M.S. Yang, and E.K. Seo, *Chem. Pharm. Bull.* **55**, 137 (2007).
- [14] D. Takeshi, I. Takako, K. Shizuka, and N. Sansei, *Chem. Pharm. Bull.* **34**, 523 (1986).
- [15] T. Hiroki, H. Sueo, and N. Sansei, *Chem. Pharm. Bull.* **33**, 1232 (1985).
- [16] O. Hofer and R. SchÖlm, *Tetrahedron* **37**, 1181 (1981).
- [17] T. Yoshio, M. Chieko, M. Toshiya, H. Eiji, T. Anki, and O. Hideaki, *Phytochemistry* **49**, 2137 (1998).
- [18] M.M.A. Rahman, P.M. Dewick, D.E. Jackson, and J.A. Lucas, *Phytochemistry* **29**, 1971 (1990).
- [19] J.K. Xu, T.L. Zhang, G.Q. Yi, Y. Xu, H.H. Wu, and Y.H. Pei, *J. Shenyang Pharm. Univ.* **27**, 429 (2010).
- [20] T. Mosmann, *J. Immunol. Methods* **65**, 55 (1983).